Immunocytokines with Activity-on-demand by Combination with Small Molecule Inhibitors
Overview
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Dakhel S, Ongaro T, Gouyou B, Matasci M, Villa A, Neri D
. Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade. Oncotarget. 2019; 10(62):6678-6690.
PMC: 6877107.
DOI: 10.18632/oncotarget.27320.
View
2.
Gout D, Groen L, van Egmond M
. The present and future of immunocytokines for cancer treatment. Cell Mol Life Sci. 2022; 79(10):509.
PMC: 9448690.
DOI: 10.1007/s00018-022-04514-9.
View
3.
Hutmacher C, Neri D
. Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy. Adv Drug Deliv Rev. 2018; 141:67-91.
DOI: 10.1016/j.addr.2018.09.002.
View
4.
Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C
. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer. 2010; 46(16):2926-35.
DOI: 10.1016/j.ejca.2010.07.033.
View
5.
Leclercq G, Steinhoff N, Haegel H, De Marco D, Bacac M, Klein C
. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. Oncoimmunology. 2022; 11(1):2083479.
PMC: 9176235.
DOI: 10.1080/2162402X.2022.2083479.
View